Trials / Not Yet Recruiting

Not Yet RecruitingNCT07327697

A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjects

A Randomized, Double-blinded, Parallel, Positive-controlled Study to Compare the Pharmacokinetic, Safety and Immunogenicity of Single-dose QL2302 vs. Tezspire ® in Healthy Subjects

Status: Not Yet Recruiting
Phase: Phase 1
Study type: Interventional
Enrollment: 178 (estimated)

Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
Sex: All
Age: 18 Years – 45 Years
Healthy volunteers: Accepted

Summary

This is a randomized, double-blinded, controlled Phase 1 study to compare the pharmacokinetic, safety and immunogenicity of QL2302 versus Tezspire®（Tezepelumab） in healthy subjects after a single dose.

Conditions

Healthy Participants

Interventions

Type	Name	Description
DRUG	QL2302	210mg/1.91mL; single dose; subcutaneous injection
DRUG	Tezspire	210mg/1.91mL; single dose; subcutaneous injection

Timeline

Start date: 2025-12-22
Primary completion: 2026-07-01
Completion: 2026-09-01
First posted: 2026-01-08
Last updated: 2026-01-08

Source: ClinicalTrials.gov record NCT07327697. Inclusion in this directory is not an endorsement.